Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNavidea Biopharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q2 2025 | 1 | -$0.09 | -$0.09 | -$0.09 |
| Q3 2025 | 1 | -$0.12 | -$0.12 | -$0.12 |
| Q4 2025 | 1 | -$0.08 | -$0.08 | -$0.08 |
| Q1 2026 | 1 | -$0.09 | -$0.09 | -$0.09 |
| Q2 2026 | 1 | -$0.09 | -$0.09 | -$0.09 |
| Q3 2026 | 1 | -$0.03 | -$0.03 | -$0.03 |
| Q4 2026 | 1 | -$0.08 | -$0.08 | -$0.08 |
| Q1 2027 | 1 | -$0.09 | -$0.09 | -$0.09 |
| Q2 2027 | 1 | -$0.09 | -$0.09 | -$0.09 |
| Q3 2027 | 1 | -$0.03 | -$0.03 | -$0.03 |
Navidea Biopharmaceuticals, Inc. Earnings Date And Information
Navidea Biopharmaceuticals, Inc. last posted its earnings results on Wednesday, March 23rd, 2022. The company reported $-0.12 earnings per share for the quarter, missing analysts' consensus estimates of $-0.03 by $0.09. The company had revenue of 0 for the quarter and had revenue of 65,652 for the year. Navidea Biopharmaceuticals, Inc. has generated $-1 earnings per share over the last year ($-0.56 diluted earnings per share) and currently has a price-to-earnings ratio of -0. Navidea Biopharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, January 6th, 2025 based on prior year's report dates.
Navidea Biopharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2023 | Q3 2023 | N/A | -$0.02 | N/A | $0 | $0 |
| 08/11/2023 | Q2 2023 | N/A | $0.12 | N/A | N/A | $0 |
| 05/11/2023 | Q1 2023 | N/A | -$0.02 | N/A | N/A | $0 |
| 03/27/2023 | Q4 2022 | N/A | -$0.11 | N/A | N/A | $610 |
| 11/14/2022 | Q3 2022 | N/A | -$0.19 | N/A | N/A | $7,516 |
| 08/15/2022 | Q2 2022 | N/A | -$0.10 | N/A | N/A | $6,519 |
| 05/16/2022 | Q1 2022 | N/A | -$0.10 | N/A | N/A | $0 |
| 03/28/2022 | Q4 2021 | N/A | -$0.12 | N/A | N/A | $50,348 |
| 11/12/2021 | Q3 2021 | N/A | -$0.08 | N/A | $600,000 | $96,382 |
| 08/12/2021 | Q2 2021 | N/A | -$0.09 | N/A | $600,000 | $261,046 |
| 05/13/2021 | Q1 2021 | N/A | -$0.11 | N/A | N/A | $123,737 |
| 03/26/2021 | Q4 2020 | N/A | -$0.11 | N/A | N/A | $219,251 |
| 11/13/2020 | Q3 2020 | N/A | -$0.11 | N/A | $300,000 | $6,773 |
| 08/14/2020 | Q2 2020 | N/A | -$0.10 | N/A | $600,000 | $8,920 |
| 05/15/2020 | Q1 2020 | N/A | -$0.13 | N/A | N/A | $15,221 |
| 03/18/2020 | Q4 2019 | N/A | -$0.15 | N/A | N/A | $2,680 |
| 11/08/2019 | Q3 2019 | N/A | -$0.17 | N/A | N/A | $4,895 |
| 08/09/2019 | Q2 2019 | N/A | -$0.24 | N/A | $162,557 | $15,893 |
| 05/09/2019 | Q1 2019 | N/A | -$0.24 | N/A | N/A | $97,558 |
| 03/15/2019 | Q4 2018 | N/A | -$0.33 | N/A | N/A | $35,040 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Navidea Biopharmaceuticals, Inc. Earnings: FAQ's
Navidea Biopharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, January 6th, 2025 based offlast year's report dates.
The conference call for Navidea Biopharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Navidea Biopharmaceuticals, Inc.'s latest earnings report can be read online.
Navidea Biopharmaceuticals, Inc. (:NAVB) has a recorded annual revenue of $65,652.
Navidea Biopharmaceuticals, Inc. (:NAVB) has a recorded net income of $-15,177,153.Navidea Biopharmaceuticals, Inc. has generated $-0.59 earnings per share over the last four quarters.
Navidea Biopharmaceuticals, Inc. (:NAVB) has a price-to-earnings ratio of -0 and price/earnings-to-growth ratio is -0.